Search

Your search keyword '"Van der Valk, Marc"' showing total 667 results

Search Constraints

Start Over You searched for: Author "Van der Valk, Marc" Remove constraint Author: "Van der Valk, Marc"
667 results on '"Van der Valk, Marc"'

Search Results

2. Design and Implementation of a Multilevel Intervention to Reduce Hepatitis C Transmission Among Men Who Have Sex With Men in Amsterdam: Co-Creation and Usability Study

3. Assessing the HIV care continuum among transgender women during 11 years of follow‐up: results from the Netherlands’ ATHENA observational cohort

4. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

5. Biomarker Analysis Provides Evidence for Host Response Homogeneity in Patients With COVID-19

6. Care interruptions and mortality among adults in Europe and North America

8. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

9. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019

10. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

11. Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

13. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration

14. Platelets of COVID-19 patients display mitochondrial dysfunction, oxidative stress, and energy metabolism failure compatible with cell death

15. All-cause hospitalisation among people living with HIV according to gender, mode of HIV acquisition, ethnicity, and geographical origin in Europe and North America: findings from the ART-CC cohort collaboration

16. Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis

17. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

18. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

19. Long-term evolution of comorbidities and their disease burden in individuals with and without HIV as they age: analysis of the prospective AGEhIV cohort study

20. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019

24. Reinfection incidence and risk among people treated for recent hepatitis C virus infection

26. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium

27. Hepatitis C Elimination in the Netherlands (CELINE): How nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination

28. Barriers and missed opportunities in PrEP uptake, use and care among men who have sex with men with recent HIV infection in the Netherlands.

30. Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort.

31. HIV prevention and missed opportunities among people with recently acquired HIV infection: Α protocol for a systematic review.

33. Chronic liver enzyme elevation and use of contemporary ARVs among persons living with HIV

34. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

35. Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort

37. Clinical features and prognostic factors in Covid-19: A prospective cohort study

39. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study

40. HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983–2015.

41. Sources of Human Immunodeficiency Virus Infections Among Men Who Have Sex With Men With a Migration Background: A Viral Phylogenetic Case Study in Amsterdam, The Netherlands.

43. Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.

44. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study

45. Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study

46. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

47. Socio-economic factors associated with loss to follow-up among individuals with HCV: A Dutch nationwide cross-sectional study

48. Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis

49. Chronic Liver Enzyme Elevation and Use of Contemporary ARVs Among People With HIV

50. Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study

Catalog

Books, media, physical & digital resources